The neurological update: therapies for cerebellar ataxias in 2020.

Gandini, J; Manto, Mario; Brémovà-Ertl, T.; Feil, K; Strupp, M (2020). The neurological update: therapies for cerebellar ataxias in 2020. Journal of neurology, 267(4), pp. 1211-1220. Springer-Medizin-Verlag 10.1007/s00415-020-09717-3

[img] Text
Gandini, 2020, The neurological update.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (526kB) | Request a copy

Cerebellar ataxias (CAs) represent a heterogeneous group of sporadic or inherited disorders. The clinical spectrum of CAs is continuously expanding. Our understanding of the mechanisms leading to the clinical deficits has improved over these last decades, in particular thanks to progress in genetics, neuroimaging and the advent of relevant animal models allowing the identification of the pathophysiological pathways leading to CAs. The rationale behind treatments is now established for most of the CAs encountered during daily practice worldwide. In this update, we will discuss the symptomatic, physical and occupational therapies now being trialled along with individualized exercises, and present key emerging issues on immune-mediated cerebellar ataxias, hereditary cerebellar ataxias. Finally, we will discuss novel therapeutic approaches, including cerebellar non-invasive stimulation and treatments acting on RNA/proteins. So far, no state-of-the art randomized placebo-controlled clinical trial has shown a convincing clinically relevant efficacy of any drug, with the exception of 4-aminopyridine for the symptomatic treatment of episodic ataxia type 2 and downbeat nystagmus (placebo-controlled trials).

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurology

UniBE Contributor:

Brémovà-Ertl, Tatiana

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0340-5354

Publisher:

Springer-Medizin-Verlag

Language:

English

Submitter:

Chantal Kottler

Date Deposited:

07 Jul 2020 14:34

Last Modified:

03 Aug 2020 19:27

Publisher DOI:

10.1007/s00415-020-09717-3

PubMed ID:

32002650

Uncontrolled Keywords:

Ataxias Cerebellum DNA RNA Therapies

BORIS DOI:

10.7892/boris.145011

URI:

https://boris.unibe.ch/id/eprint/145011

Actions (login required)

Edit item Edit item
Provide Feedback